$930.67
-42.69-4.39%
Last update: Nov 5, 3:59 AM
Regeneron Pharmaceuticals Inc (REGN) Stock Price, Quote, News & History
REGNNASDAQ
Regeneron beat Q3 estimates with EPS up 70% and revenue up 36%; analysts raised price targets to as high as $1,175.
You can purchase shares of Regeneron Pharmaceuticals (NASDAQ:REGN) through any online brokerage.
Other companies in Regeneron Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Regeneron Pharmaceuticals has a consensus price target of $887.26.
The stock price for Regeneron Pharmaceuticals (NASDAQ: REGN) is $931.34 last updated November 5, 2026 at 3:59 AM EST.
There are no upcoming dividends for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet...
